Search

Displaying results 761 - 770 of 840 in total
  1. Drug

    Remestemcel-L

    go.drugbank.com/drugs/DB13973
    ApprovedInvestigationalWithdrawn

    It is estimated that the patients with the most severe forms of refractory aGvHD that do not respond to steroid therapy have expected one-year survival rates of only 5% to 30% [L11022].

  2. Drug

    Ifenprodil

    go.drugbank.com/drugs/DB08954
    ApprovedInvestigationalWithdrawn

    [A220118, A220128] One such allosteric regulator is ifenprodil, which was first shown to bind the NMDARs in the 1990s, and specifically to those NMDARs containing the GluN2B subunit.

  3. Drug

    Placental Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15730
    Investigational

    The placenta serves many purposes, with one of the many being a bank of mesenchymal stem cells (MSCs).

  4. Drug

    Ohmefentanyl

    go.drugbank.com/drugs/DB01570
    ExperimentalIllicit

    Ohmefentanyl is one of the most potent μ -receptor agonists known, comparable to super-potent opioids such as carfentanil and etorphine which are used for tranquilizing large animals such as elephants

  5. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic n...

  6. Drug

    Pheniramine

    go.drugbank.com/drugs/DB01620
    Approved

    Pheniramine is a first-generation antihistamine in the alkylamine class, similar to brompheniramine and chlorpheniramine. It is used in some over-the-counter allergy as well as cold & flu products in combination with other drugs. Phe...

    Mixtures: Care One Flu and Sore Throat
  7. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to brexucabtagene autoleucel and axicabtagene ciloleucel. Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD1...

  8. Drug

    GFT14

    go.drugbank.com/drugs/DB05061
    Experimental

    GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease.

  9. Drug

    Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media

    go.drugbank.com/drugs/DB15728
    Experimental

    One of these companies, Aspire, has created their own product, ACT-20 Conditioned Medium as a product for testing.

  10. Drug

    Eniluracil

    go.drugbank.com/drugs/DB03516
    Investigational

    Eniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’